作者: Kiyomi Taniyama , Hiromichi Sumiyoshi , Eiichi Tahara , Wataru Yasui , Shinji Nagae
DOI: 10.20772/CANCERSCI1985.77.2_145
关键词: Biologic marker 、 Carcinoma 、 Pathology 、 Immunohistochemistry 、 Epidermal growth factor 、 Malignancy 、 Biology 、 Adenocarcinoma 、 Stomach 、 Fibrosis
摘要: The presence of human epidermal growth factor (hEGF) was studied in a total 210 gastric carcinomas comprising 52 early carcinomas, 113 advanced and 45 scirrhous carcinomas. An immunohistochemical study revealed no hEGF-immunoreactivity while hEGF-positive tumor cells were detected 24 (21.2%) the 15 (33.3%) incidence well-differentiated adenocarcinomas significantly higher than that poorly differentiated (P less 0.05). Moreover, hEGF-immunoreactive observed 13 (30.4%) 42 adenocarcinomas, being non-scirrhous average hEGF content tissue estimated by radioimmunoassay 3.77 +/- 0.61 (mean SE) ng/g wet weight tumors 2.19 0.18 hEGF-negative tumors, difference significant Patients with (excluding carcinomas) had much worse prognosis those These results suggest EGF produced plays an important role invasive productive fibrosis carcinoma also serves as biologic marker high malignancy patients cancers.